C.M. Bidwell & Associates’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.59K Sell
78
-40
-34% -$1.93K ﹤0.01% 363
2026
Q2
$6.93K Hold
118
– – ﹤0.01% 309
2026
Q1
$3.8K Hold
118
– – ﹤0.01% 356
2025
Q4
$4.97K Hold
118
– – ﹤0.01% 326
2025
Q3
$4.05K Hold
118
– – ﹤0.01% 354
2025
Q2
$3.19K Sell
118
-16
-12% -$463 ﹤0.01% 361
2025
Q1
$3.97K Buy
134
+4
+3% +$152 ﹤0.01% 335
2024
Q4
$5.15K Hold
130
– – ﹤0.01% 330
2024
Q3
$4.42K Hold
130
– – ﹤0.01% 348
2024
Q2
$2.82K Hold
130
– – ﹤0.01% 393
2024
Q1
$2.88K Hold
130
– – ﹤0.01% 395
2023
Q4
$3.58K Buy
130
+12
+10% +$290 ﹤0.01% 361
2023
Q3
$2.64K Hold
118
– – ﹤0.01% 428
2023
Q2
$3K Hold
118
– – ﹤0.01% 425
2023
Q1
$2.63K Hold
118
– – ﹤0.01% 430
2022
Q4
$2.8K Buy
118
+78
+195% +$1.81K ﹤0.01% 407
2022
Q3
$1K Hold
40
– – ﹤0.01% 467
2022
Q2
$1K Hold
40
– – ﹤0.01% 479
2022
Q1
$1K Buy
+40
New +$1.14K ﹤0.01% 517
2020
Q1
– Sell
-2,860
Closed -$80K – 465
2019
Q4
$80K Hold
2,860
– – 0.07% 173
2019
Q3
$69K Sell
2,860
-495
-15% -$13.2K 0.07% 224
2019
Q2
$96K Sell
3,355
-690
-17% -$17.2K 0.1% 179
2019
Q1
$101K Buy
+4,045
New +$77.2K 0.1% 175

Other funds holding VCYT

C.M. Bidwell & Associates's VCYT Position: Q3 2026 in Review

C.M. Bidwell & Associates reduced its Veracyte (VCYT) stake by 34% in Q3 2026, selling an estimated $1.93K and leaving 78 shares worth $3.59K. The position accounts for ﹤0.01% of the portfolio, ranked #363.

C.M. Bidwell & Associates first reported a position in VCYT in Q1 2019 and has held it in 23 quarters since. The position peaked at $101K in Q1 2019. 383 funds tracked by Wall St. Rank hold VCYT as of Q3 2026.

  • C.M. Bidwell & Associates held 78 shares of Veracyte worth $3.59K as of Q3 2026.
  • C.M. Bidwell & Associates sold 40 Veracyte shares in Q3 2026, an estimated $1.93K.
  • Veracyte made up ﹤0.01% of C.M. Bidwell & Associates's portfolio in Q3 2026, its #363 holding.
  • C.M. Bidwell & Associates first reported a position in Veracyte in Q1 2019 and has held it in 23 quarters since.
  • C.M. Bidwell & Associates's Veracyte position peaked at $101K in Q1 2019.
  • 383 funds tracked by Wall St. Rank held Veracyte as of Q3 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2026, filed 17 Nov 2026.